Viloxazine was marketed as an antidepressant in Europe for more than 2 decades under an immediate-release formulation before its potential as a treatment for patients with attention-deficit hyperactivity disorder (ADHD) was considered. Viloxazine received its first endorsement in the United Kingdom in 1971 and was subsequently recognized as an antidepressant in several other nations. However, commercial reasons led to its discontinuation in 2002. In April 2021, the U.S. Food and Drug Administration (FDA) approved viloxazine extended-release capsules for children and adolescents with ADHD. Research suggests that the mechanism of action of viloxazine is closely linked to inhibiting the reuptake of norepinephrine. Notably, the (S) stereoisomer of viloxazine exhibits 10 times greater potency than the (R) stereoisomer. This activity provides a comprehensive summary of the essential aspects of viloxazine therapy in the clinical setting, including indications, administration, doses, contraindications, mechanism of action, adverse events, and other crucial information relevant to the interprofessional team responsible for managing and treating ADHD in patients.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/139274
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, All Practice Areas (e.g. ethics), Developmental-Behavioral Pediatrics, General Pediatrics, General Surgery, Internal Medicine, Medical Toxicology, Neurodevelopmental Disabilities